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Abstract
Background: Post-transplant lymphoproliferative disorder (PTLD) adversely affects patients’ long-term outcome.
Methods: The paired t test and McNemar’s test were applied in a retrospective 1:1 matched-pair analysis including
36 patients with PTLD and 36 patients without PTLD after kidney or liver transplantation. Matching criteria were age,
gender, indication, type of transplantation, and duration of follow-up. All investigated PTLD specimen were histologically
positive for EBV. Risk-adjusted multivariable regression analysis was used to identify independence of risk factors for PTLD
detected in matched-pair analysis. The resultant prognostic model was assessed with ROC-curve analysis.
Results: Patients suffering with PTLD had shorter mean survival (p = 0.004), more episodes of CMV infections or
reactivations (p = 0.042), and fewer recipient HLA A2 haplotypes (p = 0.007), a tacrolimus-based immunosuppressive
regimen (p = 0.052) and higher dosages of tacrolimus at hospital discharge (Tac dosage) (p = 0.052). Significant
independent risk factors for PTLD were recipient HLA A2 (OR = 0.07, 95 % CI = 0.01–0.55, p = 0.011), higher Tac
dosages (OR = 1.29, 95 % CI = 1.01–1.64, p = 0.040), and higher numbers of graft rejection episodes (OR = 0.38,
95 % CI = 0.17–0.87, p = 0.023). The following prognostic model for the prediction of PTLD demonstrated good
model fit and a large area under the ROC curve (0.823): PTLD probability in % = Exp(y)/(1 + Exp(y)) with y = 0.671
− 1.096 × HLA A2-positive recipient + 0.151 × Tac dosage − 0.805 × number of graft rejection episodes.
Conclusions: This study suggests prognostic relevance for recipient HLA A2, CMV, and EBV infections or reactivations
and strong initial tacrolimus-based immunosuppression. Patients with risk factors may benefit from intensified
screening for PTLD.
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Background
Post-transplant lymphoproliferative disorders (PTLD)
are a heterogeneous group of diseases [1]. A clear defin-
ition is difficult since PTLD include a wide spectrum
from lymphoid hyperplasia, like mononucleosis, to atyp-
ical lymphoid hyperplasia with beginning effacement of
normal tissue architecture, to an infiltrative type of poly-
clonal to monoclonal lymphoma [2, 3]. Despite these
taxonomical imprecisions, PTLD is clearly a serious and
life-threatening complication after transplantation with a
high mortality rate of 30–60 % [4].
The underlying disease leading to transplantation might
have an influence on the risk of developing PTLD [5]. It
was reported that patients under the age of 10, as well as
patients over 60 years of age, are more likely to develop
PTLD [1, 6–8]. Furthermore, pre-transplant malignancy is
supposed to increase the risk of PTLD [1, 9, 10]. Human
leukocyte antigen (HLA) types HLA-A2, HLA-A11, HLA-
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B5, HLA-B18, HLA-B21, and HLA-B35 in transplant
recipients as well as HLA-B40 group in EBV-seropositive
and HLA-B8 in EBV-seronegative patients were described
to be associated with an increased risk for PTLD,
whereas HLA-A3 and HLA-DR7 appear to decrease the
risk [11–13]. Beside the recipients’ HLA status, the do-
nors’ HLA typing result as well as the matching or mis-
matching of both seems to have an influence on the
development of PTLD [1, 4, 14–16].
There is some evidence that the type and intensity
of immunosuppression influences the risk of PTLD
[7–9, 17–23].
The majority of PTLDs are associated with EBV infec-
tion [1, 24–29], and thus the risk for PTLD depends on
the donor’s and recipient’s EBV status [1, 24, 29, 30]. In
conjunction with this observation, it has been described
that antiviral agents, such as ganciclovir, aciclovir, and
foscarnet, may be useful for therapy and prophylaxis of
EBV-related PTLD [1, 31–34].
Coexisting CMV infection might be a risk factor for
PTLD [7, 35, 36]. However, this association has not been
confirmed yet [5, 37, 38]. Infections with the hepatitis C
virus and human herpes virus 8 have also been described
as risk factors for PTLD [1, 36, 39, 40].
This study aims to evaluate the relevance of risk factors
for PTLD development in adult and pediatric patients
after primary kidney or liver transplantation independent
of age, gender, indication for transplantation, type of
transplantation, year of transplantation, and duration of




A university hospital in Germany provides the setting
within the Eurotransplant community.
Study type and study population
This is a single-center retrospective observational 1:1
matched-pair analysis based on 2897 patients who under-
went primary liver transplantation between 01.01.1983
and 31.12.2012, as well as 1895 patients who underwent
primary kidney transplantation between 01.01.2000 and
31.12.2012 at Hannover Medical School. Combined trans-
plants were excluded due to a lack of adequate matching
partners.
Definition of matching criteria
Each analyzed case with PTLD during follow-up was
matched with one non-PTLD case applying the matching
criteria age at transplantation, gender, indication for trans-
plantation, type of transplantation, year of transplantation,
and duration of post-transplant follow-up. In non-PTLD
patients, the duration of follow-up for matching was de-
fined as time to PTLD diagnosis of the matching partner.
Definition of analyzed variables
Concerning donor and recipient HLA status, we only
considered the donors’ HLA of the actual transplanted
organ at PTLD diagnosis, which may be relevant in cases
with multiple transplants during follow-up (n = 5). The
same principle was applied to the matching partners with-
out PTLD with subsequent transplants during follow-up
(n = 6): the donors’ HLA at the equivalent time point to
the diagnosis of PTLD in the corresponding partner was
considered.
Borderline changes in the transplanted organ were cate-
gorized according to the Banff classification and classified
as graft rejections for the purpose of this study, because
these changes were typically treated with high dose ste-
roids, just as in acute graft rejection which is common
practice in many centers [41].
In the absence of an explicit proof of infection, chil-
dren under the age of 1 year were considered seronega-
tive for viral infections as maternal antibodies may give
false positive antibody status [21].
Quantitative data on immunosuppressive therapy of our
patients was collected from hospital discharge after trans-
plantation until the time of PTLD diagnosis or equivalent
time periods for the non-PTLD matching partners. The
duration of given immunosuppressive drugs in months
and all changes of the type of immunosuppression were
analyzed, and percentages of the follow-up time with ei-
ther ciclosporine-based or tacrolimus-based immunosup-
pression were calculated. If a patient was not receiving
tacrolimus, ciclosporine, etc., the value was set to zero.
Statistical methods
In matched-pair analysis, all continuous variables were
analyzed using the paired t test while binominal vari-
ables were analyzed using McNemar’s test. Multivariable
principal component analysis was used to understand
the underlying data structure and to define uncorrelated
variables for prognostic score design by avoiding multi-
collinearity in regression (Fig. 1). After exclusion of mul-
ticollinearity, all variables with an alpha-error <0.200 in
univariable analyses (paired t test for continuous vari-
ables and McNemar’s test for binominal variables) were
included into multivariable conditional logistic regres-
sion analysis for binary matched pairs as described by
Agresti [42] with the goal to develop a regression model
for the prediction of PTLD and to identify significant
risk-adjusted independent risk factors for PTLD. Model
fit was assessed for regression models using Hosmer-
Lemeshow’s chi-square test. ROC-curve analysis was
performed to calculate the sensitivity and specificity of
the derived regression model for the prediction of PTLD
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[43, 44]. Determination of the area under the ROC-
curve (AUROC) was used to assess the potential clinical
usefulness of the final prediction model [43, 44] derived
with the logit link function.
All p values <0.05 were defined as significant. Analyses
were performed using JMP® software, version 11, from
SAS Institute Inc., Cary, NC, USA.
Results
Identification of PTLD cases and their inclusion into
matched-pair analysis
A total of 41 cases with PTLD were identified. Thirty-six
of these 41 patients with PTLD were included into the
matched-pair analysis, with 16 of them being primary
kidney-transplanted patients and 20 primary liver trans-
planted patients. Five patients with PTLD were excluded
due to the lack of available data on important risk fac-
tors or inability to find an appropriate matching case
without PTLD during follow-up.
Within the group of 16 kidney-transplanted patients,
nine were female and seven were male with nine being
transplanted as a child and seven as an adult. The me-
dian age at the transplantation of kidney-transplanted
patients with PTLD was 14.4 years (mean age 23.6 years)
whereas the median age of their non-PTLD counterparts
was 15.6 years (mean age 26.6). All of them were trans-
planted between 2000 and 2010. The underlying diseases
leading to transplantation form a heterogeneous group
of diseases, varying between different types of glomer-
ulonephritis to kidney dysplasia, autosomal dominant
polycystic disease, hemolytic-uremic syndrome, and
others.
Within the group of 20 liver-transplanted patients, five
were female and 15 were male with 12 of them being
transplanted as a child and eight being transplanted as
an adult. The median age at transplantation in the PTLD
group was 5.5 years (mean age 21.2 years) as compared to
7.8 years (mean age 21.3 years) in the non-PTLD group.
Here, the underlying diseases leading to transplantation
Fig. 1 Shown is the result of principal component analysis of analyzed risk factors prior to inclusion into multivariable regression models.
This result demonstrates lack of relevant multicollinearity of these factors
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were biliary atresia in many cases and less frequently pri-
mary sclerosing cholangitis, viral-related cirrhosis and
acute liver failure.
The mean differences of the date of transplantation and
the age at transplantation between matches were 0.02 days
(standard error 103.8 days, p = 0.147; paired t test) and
0.04 years (standard error 0.33 years, p = 0.901; paired
t test), respectively. All other matching criteria were
100 % identical matches.
Clinicopathological characteristics of analyzed PTLD cases
Within 36 analyzed PTLD cases, 16 underwent kidney
transplantation and 20 underwent liver transplantation.
Twenty-one of 36 patients were transplanted as chil-
dren (age <17 years) and 15 as adults, with 19 of them
being diagnosed for PTLD during childhood (8 kidney-
transplanted cases and 11 liver-transplanted cases) ver-
sus 17 adult PLTD patients. The mean time to PTLD
diagnosis was 3.8 years, and the median age of the patients
at PTLD diagnosis was 15.7 years (range 0.8–70.8 years,
mean 26.1 years).
Overall mortality during follow-up was 36.1 % in PTLD
patients with a mean survival of 294 days after PTLD diag-
nosis (median 119 days, range 11–953 days). Eleven of the
13 patients who died after PTLD diagnosis had a late
PTLD (>365 days after transplantation) and one had a very
early PTLD (<183 days after transplantation). The mean
age at PTLD diagnosis of these 13 PTLD cases that sub-
sequently died was 32.7 years (median 43.4 years, range
2.2–63.8 years). All of them died after 01.01.2000, and 5 of
these patients died after 01.01.2010. Twelve of these 13 pa-
tients had a monomorphic PTLD while 8 of them had
PTLD disease classified as diffuse large B-cell lymphoma.
Ten of the deceased patients had extranodal disease
with five patients suffering from CNS involvement and
three patients having a primary CNS lymphoma. Six of
these 13 patients were treated with rituximab with or
without chemotherapy and five patients were treated
with radiotherapy. In six of 11 patients who subsequently
died, immunosuppressive therapy was changed after PTLD
diagnosis while in five of 11 patients who died received
antiviral therapy.
The distributions of the clinicopathological character-
istics of 36 analyzed PTLD cases are summarized in
Table 1.
Survival in PTLD versus matched non-PTLD patients
Only in one pair the non-PTLD patient died within the
timeframe in which the PTLD-match was still alive. In
contrast, 11 PTLD patients died during follow-up while
their non-PTLD matching partners continued to survive
(p = 0.004, McNemar’s test) (Table 2). Mean survival
after the transplantation of PTLD patients (7.74 years)
was significantly shorter as compared to the matched
non-PTLD partners (9.98 years) (p = 0.004, paired t test)
(Table 3, Fig. 2).
Significant risk factors for PTLD development in
matched-pair analysis
The number of episodes of CMV de novo infections or
reactivations showed a significant difference between
PTLD cases (mean: 1.47) and their non-PTLD matching
partners (mean: 0.75) (p = 0.042, paired t test) (Table 3,
Fig. 3).
The recipients’ HLA A2 was significantly more fre-
quent in the non-PTLD matching partners. In 10 out
of 19 analyzed pairs, the PTLD patient was negative
for HLA A2 while the matching partners were HLA
A2 positive and only in one discordant pair, we
found the opposite result (p = 0.007, McNemar’s test)
(Table 2).
Immunosuppression with tacrolimus at the time of hos-
pital discharge after transplantation was associated with
later development of PTLD (p = 0.052; McNemar’s test). In
ten pairs, the patient with PTLD was treated with tacroli-
mus at hospital discharge while their respective matching
partners received ciclosporine-based immunosuppression
instead. In three discordant cases, the opposite was the
case (Table 2). The mean daily dose of tacrolimus at hos-
pital discharge was significantly higher within the PTLD
group (3.74 mg) as compared to their non-PTLD matching
partners (1.62 mg) (p = 0.052, paired t test) (Table 3, Fig. 4).
However, blood levels of tacrolimus or ciclosporine (trough
blood level as well as blood level 2 hours after oral intake)
at hospital discharge did not show to be significantly differ-
ent between matched pairs (Table 3). Immunosuppressive
induction therapy with anti-thymocyte globulin (ATG),
basiliximab, and daclizumab did not differ significantly
between PTLD and non-PTLD patients. In matched-pair
analysis, an equal number of discordant pairs resolved
in a non-significant p value for immunosuppressive in-
duction therapies either with basiliximab or daclizumab
(Table 2).
All other analyzed risk factors did not show any statis-
tically significant differences between the PTLD cases
and their matched controls (Tables 2 and 3). In particu-
lar, the recipients’ EBV serology status at transplantation
was not significantly different between PTLD cases and
their matching partners (p > 0.05, McNemar’s test). In
four pairs, the PTLD patient was EBV IgG negative at
transplantation and the matching non-PTLD partner
was EBV IgG positive, whereas in two pairs, the opposite
was observed with the PTLD case EBV IgG positive and
the matching partner EBV IgG negative at transplant-
ation (p = 0.414; McNemar’s test). Analysis of ganciclovir
or valganciclovir treatment after transplantation revealed
seven matching pairs where the PTLD patient did not
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receive ganciclovir or valganciclovir when the non-
PTLD patient did, whereas in nine matching pairs, this
was the opposite (p = 0.617; McNemar’s test).
Independent risk factors for PTLD development in
multivariable conditional logistic regression
Multivariable conditional regression analysis revealed
that HLA A2 in the transplant recipient (odds ratio
(OR) 0.07, 95 % CI 0.01–0.55, p = 0.011), the level of
tacrolimus dosing at hospital discharge after trans-
plantation (OR 1.29, 95 % CI 1.01–1.64, p = 0.040)
and the number of graft rejection episodes (OR 0.38,
95 % CI 0.17–0.87, p = 0.023) were independent sig-
nificant risk factors after risk adjustment for the
matching criteria and the included variables with p
values <0.200 in univariable analyses (Tables 2 and 3).
Multivariable principal component analysis demon-
strated lack of multicollinearity between these vari-
ables (Fig. 1).
Table 1 Clinicopathological characteristics of all PTLD patients
Variable Distribution
Age at transplantation in years Median: 12.7 (0.4–65.4);
mean: 22.3
Time to diagnosis after transplantation in years Median: 2.1 (0.3–19);
mean: 3.8
Age at PTLD diagnosis in years Median: 15.7 (0.8–70.8);
mean: 26.1
Age > 60 years at PTLD diagnosis n = 4 (11.1 %)
Age < 10 years at PTLD diagnosis n = 14 (38.9 %)
Age < 5 years at PTLD diagnosis n = 11 (30.6 %)
Late PTLD (>365 days after Tx) n = 24 (66.7 %)
Very early PLTD (<183 days after Tx) n = 4 (11.1 %)
Ciclosporine at PTLD diagnosis n = 15 (41.7 %)
Tacrolimus at PTLD diagnosis n = 16 (44.4 %)
CNI-free immunosuppression at PTLD diagnosis n = 5 (13.9 %)
Mycophenolat at PTLD diagnosis n = 19 (52.8 %)
Steroids at PTLD diagnosis n = 29 (80.6 %)
Steroid-free immunosuppression at PTLD
diagnosis
n = 7 (19.4 %)
mTOR inhibitors at PTLD diagnosis n = 1 (2.8 %)




Number of graft rejections after PTLD diagnosis Median: 0 (0–1);
mean: 0.25
Polymorphic PTLD n = 5 (13.9 %)
Monomorphic PTLD n = 28 (77.8 %)
Pure B cell neoplasm n = 29 (80.6 %)
Diffuse large B cell neoplasm n = 20 (55.6 %)
CD20 expression in tumor n = 32 (88.9 %)
EBV latent membrane protein or EBV-encoded
RNA in tumor cells
n = 26 (100.0 %a,
10 cases missing data)
Detection of monoclonal disease n = 9 (52.9 %a,
19 cases missing data)
Extranodal disease n = 24 (66.7 %)
Graft organ involvement n = 4 (11.1 %)
CNS involvement n = 7 (19.4 %)
Primary CNS lymphoma n = 4 (11.1 %)
Bone marrow involvement n = 6 (16.7 %)
Gastro-intestinal involvement n = 14 (38.9 %)
Lung involvement n = 3 (8.3 %)
Skin involvement n = 0 (0.0 %)
Number of sites involved Median: 2 (1–6);
mean: 2.5
Stage IV disease n = 25 (69.4 %)
B-symptoms at PTLD diagnosis n = 4 (11.1 %)
Lactate dehydrogenase elevated at PTLD
diagnosis
n = 23 (71.9 %a,
4 cases missing data)
Hypoalbuminemia at PTLD diagnosis n = 17 (65.4 %a,
10 cases missing data)
Table 1 Clinicopathological characteristics of all PTLD patients
(Continued)
EBV IgG at Tx n = 14 (45.2 %a,
5 cases missing data)
EBV IgM at Tx n = 1 (3.3 %a,
6 cases missing data)
EBV serology or DNA positive at PTLD diagnosis n = 31 (100.0 %a,
5 cases missing data)
EBV DNA at PTLD diagnosis n = 29 (96.7 %a,
6 cases missing data)
EBV IgG at PTLD diagnosis n = 21 (77.8 %a,
9 cases missing data)
CMV IgG at Tx n = 12 (35.3 %a,
2 cases missing data)
CMV IgM at Tx n = 3 (9.7 %a,
5 cases missing data)
CMV pp65 at Tx n = 1 (3.8 %a,
10 cases missing data)
CMV serology or DNA positive at PTLD
diagnosis
n = 23 (100 %a,
13 cases missing data)
CMV pp65 at PTLD diagnosis n = 1 (4.2 %a,
12 cases missing data)
CMV DNA at PTLD diagnosis n = 4 (22.2 %a,
18 cases missing data)
CMV IgM at PTLD diagnosis n = 7 (30.4 %a,
13 cases missing data)
CMV IgG at PTLD diagnosis n = 21 (77.8 %a,
9 cases missing data)
Shown are the distributions of clinicopathological characteristics of 36
analyzed PTLD cases
Tx transplantation, CNI-free calcineurin-inhibitor-free, EBV Epstein-Barr virus,
CMV cytomegalovirus
aOf evaluated cases
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Table 2 Matched-pair analysis for binominal variables
Variables (+)/(−)a Nr. of analyzed
matched
pairs in %













Death 100.0 2 22 1 11 0.004
Subsequent re-transplants 100.0 1 26 5 4 0.739
Living Donor 100.0 4 18 5 9 0.285
BMI >30 kg/m2 100.0 0 32 2 1 0.564
Diabetes 100.0 0 32 2 2 1.000
Alcohol abuse 100.0 0 34 2 0 n.d.
Active Smoking 100.0 0 31 2 3 0.655
COPD 100.0 0 35 1 0 n.d.
Recipient EBV IgG at Tx 86.1 12 13 4 2 0.414
Recipient CMV IgG at Tx 91.7 9 15 6 3 0.317
Donor CMV IgG at Tx 97.2 13 8 5 9 0.285
Recipient Anti-HCV at Tx 61.1 0 22 0 0 n.d.
Anti-CMV treatment after Tx 100.0 10 9 7 10 0.467
Ganciclovir/valganciclovir after Tx 100.0 9 11 7 9 0.617
Pre-transplant malignancy 100.0 2 34 0 0 1.000
Pre-transplant HCC 100.0 2 34 0 0 1.000
Non-PTLD malignancy after Tx 100.0 0 31 2 3 0.655
Breast cancer after Tx 100.0 0 35 0 1 n.d.
Pre-transplant dialysis 100.0 12 20 2 2 1.000
Donor HLA A26, B38 75.0 0 25 0 2 n.d.
Donor HLA A1 75.0 1 15 5 6 0.763
Donor HLA B8 75.0 1 21 3 2 0.655
Donor HLA DR3 75.0 1 20 4 2 0.414
Recipient HLA A26, B38 52.8 0 18 0 1 n.d.
Recipient HLA A2 52.8 6 2 10 1 0.007
Recipient HLA A11 52.8 0 15 3 1 0.317
Recipient HLA B5 52.8 0 15 2 2 1.000
Recipient HLA B18 52.8 0 16 3 0 n.d.
Recipient HLA B21 52.8 0 18 1 0 n.d.
Recipient HLA B35 52.8 1 12 4 2 0.414
Recipient HLA A3 52.8 1 10 4 4 1.000
Recipient HLA DR27 52.8 0 19 0 0 n.d.
HLA A locus mismatching 47.2 7 2 3 5 0.480
HLA B locus mismatching 47.2 10 0 3 4 0.706
HLA DR locus mismatching 47.2 12 2 2 1 0.564
Anti-thymocyte globulin after Tx 86.1 0 30 1 0 n.d.
Basiliximab therapy after Tx 86.1 6 11 7 7 1.000
Daclizumab therapy after Tx 86.1 0 29 1 1 1.000
Tacrolimusc after Tx 100.0 5 18 3 10 0.052
Ciclosporinec after Tx 100.0 17 5 10 4 0.109
MMFc after Tx 100.0 10 15 5 6 0.763
Myforticc after Tx 100.0 0 35 0 1 n.d.
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Multivariable regression model for the prediction of
PTLD in matched-pair analysis
The proposed prognostic model for PTLD probability in
this matched-pair analysis has been derived with the
logit link function of the multivariable binary regression
model as:
PTLD probability in % ¼ Exp yð Þ = 1 þ Exp yð Þð Þ with
Y ¼ 0:671 − 1:096  HLA A2 positive recipient
þ 0:151  tacrolimus dose in mg at hospital discharge
after transplantation − 0:805  number of episodes of
graft rejection
Model fit assessment demonstrated a good model fit
(p = 0.483). The AUROC was assessed as 0.823 (Fig. 5).
Discussion
Advantages of the matched-pair approach
This is the first matched-pair analysis of independent risk
factors for PTLD development after kidney or liver trans-
plantation. Matched-pair analysis provides comparatively
high levels of evidence for significant findings especially in
discordant pairs and in comparatively small sample sizes
[45]. The goal of this study is to identify those patients
who are at increased risk under comparable clinical condi-
tions in order to provide a rationale for individualized
prophylactic measures, intensified screening schemes, and
patient information.
The role of risk factors for PTLD was studied inde-
pendently of age, gender, indication for transplantation,
type of transplantation, year of transplantation, and dur-
ation of follow-up by using these variables as matching
criteria because all of these factors cannot be changed by
the treating physician during follow-up. This purposefully
chosen matching approach enables the identification of
risk factors for PTLD that are independent of these cri-
teria. Some of the identified independent risk factors such
as the type and intensity of immunosuppression are under
direct control of the treating physician and can thus be al-
tered while other risk factors could be used to decide on
increased screening for PTLD.
The setting as 1:1 nearest neighbor matching as com-
pared to a larger matched control is justified due to the fact
that poor matches are avoided and an often minimal re-
duction in power of the statistical analysis is possible [46].
Some of the matching criteria have been described be-
fore to influence the risk for PTLD. Patients under the age
10, as well as patients over 60 years, are more likely to de-
velop PTLD [1, 6–8]. PTLD incidence was reported to be
lowest after renal transplantation (1–2 %) and moderate
after liver transplantation (3–12 %), compared to much
higher observed incidences after intestinal or multiorgan
transplantation [47]. Specific indications for liver trans-
plantation such as autoimmune hepatitis, primary biliary
cirrhosis, alcoholic cirrhosis, and acute liver failure appear
to relate to the risk of PTLD development [5].
This study used the duration of follow-up for match-
ing. This additional matching criterion is essential for
the detection of risk factors that are independent of
the duration of immunosuppression which is thought
to be a critical risk factor for the development of PTLD
[7–9, 17–23]. A very high percentage of patients does per-
form their follow-up in our transplant center, as there is a
defined program for monitoring each patient and their
degree of immunosuppression, especially those patients
who develop complications are monitored more closely.
Without being able to give exact numbers, loss of follow-up
is in our opinion not the reason for a rather low PTLD
incidence within our center. PLTD incidence in our cohort
was 0.86 % which is in line with other reports suggesting a
PTLD incidence after liver or kidney transplantation be-
tween 1 and 5 % [48].
The occurrence of subsequent re-transplants and the
number of subsequent transplants were not significantly
different between matched PTLD and non-PTLD cases
Table 2 Matched-pair analysis for binominal variables (Continued)
Steroidsc after Tx 100.0 32 1 1 2 0.564
Sirolimusc after Tx 100.0 0 34 1 1 1.000
Everolimusc after Tx 100.0 0 34 1 1 1.000
Azathioprinc after Tx 100.0 1 33 2 0 0.157
Tacrolimus at PTLDd 100.0 7 14 6 9 0.439
Ciclosporine at PTLDd 100.0 12 12 9 3 0.083
CNI-free treatment at PTLDd 100.0 1 30 1 4 0.180
Summarized are the results of matched-pair analysis for binominal variables. Their distribution in concordant and discordant pairs in matched-pair analysis
is shown
a(+)/(−)-classifiers identify yes/no or positive/negative variables
bMcNemar’s test for binary variables
cAt hospital discharge
dDiagnosis or equivalent date in the non-PTLD group
Tx transplantation, COPD chronic obstructive pulmonary disease, BMI body mass index, EBV Epstein-Barr virus, CMV cytomegalovirus, HCC hepatocellular carcinoma,
HCV hepatits C virus, HLA human leukocyte antigen, MMF mycophenolat mofetil, CNI calcineurin inhibitor, n.d. p value not determined due to zero cases within
pairs (McNemar’s test)
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(p = 0.739, McNemar’s test and p = 1.000, paired t test,
respectively). Therefore, the above described consider-
ation of donor and recipient HLA status at PTLD diag-
nosis or the equivalent time point during follow-up in
their corresponding matching partner appears justified.
Worse survival of patients with PTLD
Long-term survival after transplantation was signifi-
cantly shorter in the analyzed PTLD patients as com-
pared to the non-PTLD matching partners (p = 0.004).
This finding confirms the clinical relevance of PTLD
for long-term prognosis after transplantation which is
known to be a serious and life-threatening complication
after solid-organ transplantation [4].
CMV and EBV are risk factors for PTLD
This matched-pair study revealed that patients with
PTLD had significantly more episodes of cytomegalo-
virus (CMV) de novo infections or reactivations as com-
pared to their non-PTLD matching partners. This result
corresponds to other studies that found coexisting CMV
infection as a potential risk factor for PTLD [7, 35, 36].
Table 3 Matched-pair analysis for continuous variables
Variable PTLD mean Non-PTLD mean Mean difference
of Non-PTLD
minus PTLD
p valuea Standard error of
mean difference
Survival after Tx in years 7.74 9.98 2.24 0.004 0.72
PTLD-free survival in years 3.99 9.98 5.99 <0.001 0.76
Number of subsequent re-transplants 0.17 0.17 0.00 1.000 0.10
CIT in minutes 658.07 627.07 −31.00 0.756 99.05
BMI in kg/m2 20.05 20.13 0.09 0.890 0.62
Number of episodes of graft rejection 0.71 1.17 0.46 0.118 0.29
Number of episodes of EBV de novo infections or reactivations 0.50 0.50 0.00 1.000 0.15
Number of episodes of CMV de novo infections or reactivations 1.47 0.75 −0.72 0.042 0.34
Duration of pre-Tx dialysis in years 4.02 4.65 0.63 0.561 1.06
Number of HLA A locus recipient-donor mismatches 0.76 0.71 −0.06 0.791 0.22
Number of HLA B locus recipient-donor mismatches 1.12 1.06 −0.06 0.805 0.23
Number of HLA DR locus recipient-donor mismatches 0.94 1.06 0.12 0.431 0.15
Overall number of HLA recipient-donor mismatches 2.82 2.82 0.00 1.000 0.51
Daily dose of tacrolimus in mgb after Tx 3.74 1.62 −2.12 0.052 1.05
Blood level of tacrolimus in ng/mlb after Tx 9.97 8.13 −1.83 0.734 4.69
Daily dose of ciclosporine in mgb after Tx 176.17 183.06 6.89 0.832 32.24
C0 blood level of ciclosporine in μg/lb after Tx 218.46 195.91 −22.55 0.230 17.63
C2 blood level of ciclosporine in μg/lb after Tx 1183.0 1168.5 −14.5 0.909 100.5
Daily dose of MMF in mg afterb after Tx 545.00 551.67 6.67 0.967 161.43
Daily dose of prednisolone in mgb after Tx 11.13 10.99 −0.14 0.916 1.31
Daily dose of sirolimus inb after Tx 0.06 0.06 0.00 1.000 0.08
Daily dose of everolimus in mgb after Tx 0.06 0.14 0.08 0.585 0.15
Daily dose of azathioprine in mgb after Tx 2.08 2.78 0.69 0.160 0.48
Tacrolimus treatment in months c 12.47 15.62 3.15 0.596 5.87
Tacrolimus treatment in % of time of immunosuppressionc 46.87 33.45 −13.42 0.231 11.00
Ciclosporine treatment in monthsc 27.16 25.58 −1.58 0.737 4.67
Ciclosporine treatment in % of time of immunosuppressionc 46.25 59.70 13.45 0.180 9.83
CNI-free treatment in monthsc 6.96 5.29 −1.67 0.628 3.41
CNI-free treatment in % of time of immunosuppressionc 7.81 6.69 −1.11 0.803 4.42
Shown are the results of univariable matched-pair analysis for continuous variables
aPaired t test
bAt hospital discharge
cUntil PTLD diagnosis or equivalent date in the non-PTLD group)
Tx transplantation, CIT cold ischemic time, BMI body mass index, EBV Epstein-Barr virus, CMV cytomegalovirus, HLA human leukocyte antigen, C0 trough blood
level, C2 blood level 2 hours after oral intake, MMF mycophenolat mofetil, CNI calcineurin inhibitor
Rausch et al. Transplantation Research  (2016) 5:6 Page 8 of 15
Immunosuppressive therapy promotes a low control of
CMV which has been shown to interfere with the im-
mune system in vivo and in vitro [36, 49, 50]. Also, a
strong association between CMV reactivation and EBV
reactivation has been demonstrated in a study from Zallio
et al. [51]. Thus, closer monitoring for CMV activity as
well as the role of antiviral prophylaxis after transplant-
ation should not be underestimated. This approach should
be considered even in CMV IgG-positive patients as they
may reduce the PTLD incidence after transplantation.
Treatment after transplantation with antiviral agents,
such as ganciclovir, valganciclovir, or aciclovir, for which
prevention of EBV-related PTLD development has been
suggested [1, 31, 34], did not show a statistically signifi-
cant effect on the occurrence of PTLD in this study. We
conclude that antiviral prophylaxis may be ineffective for
the prevention of PTLD or, alternatively, was not con-
sistently enough or not long enough applied in the in-
vestigated cohort to enable a significant protective effect
in PTLD cases. Ganciclovir and valganciclovir are nu-
cleoside analogues that inhibit EBV DNA replication. In
cells that are latently infected with EBV and cells of
EBV-driven lymphomas, these antiviral agents appear to
be ineffective due to a lack of an activating thymidine
kinase [47].
EBV-seronegative patients were reported in a non-
matched analysis to have a 4.7-fold higher hazard ratio
for PTLD as compared to EBV-seropositive recipients
due to increased EBV infection risks [30]. However, in
the current analysis, the frequency of the recipients’
positive EBV IgG status at transplantation was not sig-
nificantly different between matching PTLD and non-
PTLD partners (Table 2).
It is striking that this first matched-pair analysis did
not find a significant risk for PTLD that is associated
with the occurrence and number of EBV infections or
reactivations after transplantation during follow-up inde-
pendent of age at transplantation.
However, all analyzed PTLD cases with available data on
EBV latent membrane protein or EBV-encoded RNA in
tumor cells (26 cases of 36 cases) were positive for EBV in
the histology specimen (Table 1). All 31 PTLD cases with
available data on EBV IgG positivity or EBV DNA posi-
tivity at the time of PTLD diagnosis were either EBV
IgG or EBV DNA positive at the time of PTLD diagno-
sis (Table 1).
These findings support the previously described strong
risk for PTLD which is associated with EBV infections
and reactivations even though the current matched-pair
analysis did not reveal a significant statistical difference
Fig. 2 Shown are the results of matched-pair analysis for patient survival after transplantation (p = 0.004; paired t test). The colored lines link values
between PTLD patients and matching non-PTLD partners, demonstrating the difference in each pair. Tx transplantation
Rausch et al. Transplantation Research  (2016) 5:6 Page 9 of 15
in the number of EBV infections or reactivation episodes
after transplantation between PTLD and matched non-
PTLD cases (Table 3). We believe that this somehow
contradictory observation may be due to the fact that
EBV infections and reactivations were frequently not de-
tected during follow-up due to subclinical symptoms. This
assumption supports the recommendation that EBV ser-
ology and EBV viral load should be monitored on a regu-
lar basis [52].
Type of immunosuppression is relevant for PTLD risk
Many authors noted that the type of immunosuppres-
sion, as well the degree of immunosuppression influ-
ences the risk of PTLD [7–9, 17–23]. This matched-pair
analysis confirms that initial tacrolimus-based immuno-
suppression after transplantation as well as high daily
doses of tacrolimus after transplantation both in-
creased the risk of later PTLD development. This cor-
responds to other reports that described a two- to
fivefold increase of PTLD risk with tacrolimus instead
of ciclosporine after pediatric and adult solid-organ
transplantation [8, 53, 54].
Interestingly, immunosuppressive induction therapy,
either with basiliximab, daclizumab, or anti-thymocyte
globulin (ATG), did not increase or decrease the risk of
PTLD development in the setting of this analysis. This
finding is based on the fact that no discordant pairs
were found where the PTLD case has received induc-
tion immunosuppression either with anti-thymocyte
globulin, basiliximab, or daclizumab while his or her
matching partner did not (Table 2).
The same non-significant result was detected for im-
munosuppressive blood levels. Neither for tacrolimus
nor for ciclosporine blood levels (C0, C2) at hospital dis-
charge, a significant difference between PTLD patients
and matched non-PTLD controls could be detected in
this study. One explanation could be that none of these
blood levels reflect the actual peak drug level which
might be the crucial factor for turning cells at risk to de-
differentiate into malignant lymphoma cells.
It is possible that other parameters such as the area
under the time curve (AUC) of calcineurin-inhibitor (CNI)
blood levels, which is known to be the biologically relevant
parameter for toxicity and the immunosuppressive effect of
these agents [55, 56], rather than trough blood levels may
Fig. 3 Shown are the results of matched-pair analysis for the number of episodes of CMV de novo infections or reactivations (p = 0.042;
paired t test). The colored lines link values between PTLD patients and matching non-PTLD partners, demonstrating the difference in each
pair. Tx transplantation, CMV cytomegalovirus
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be more relevant for the development of de novo malig-
nancy. Further, inter-individual differences concerning the
first pass metabolism in immunosuppressed patients vary
relative to CNI-absorption and thus blood levels [57, 58].
These assumptions may explain to some degree the
perceived discrepancy between the observed effects of
immunosuppressive dosages on PTLD risk while the
respective blood drug levels appeared to be less
important.
Further analysis of the duration of treatment with tacro-
limus in months as well as in percent of the time until
PTLD diagnosis or the equivalent time frame for the non-
PTLD matching partners did not reveal a statistically
significant difference between PTLD and non-PTLD pa-
tients. Similar analyses for the treatment with ciclosporine
or calcineurin-inhibitor (CNI)-free immunosuppression
during follow-up demonstrated the same non-significant
results (Table 3). We believe that analyses of the complete
immunosuppression in each individual, including all
changes of dosing and all blood level changes over time
during follow-up, are required for deeper insights into the
long-term consequences of immunosuppression. Dosages
in children are usually adapted to their body weight or
body surface and blood levels. Nevertheless, we believe
that analysis of absolute dosages in combination with
blood levels in this study provides reasonable results due
to the tight matching for age and duration of follow-up in
matched-pair analysis.
The duration of immunosuppression could not be iden-
tified as a prognostic variable for PTLD development in
this study, because the duration of follow-up after trans-
plantation was used as one of the matching criteria.
The role of graft rejection and HLA haplotypes
The number of graft rejection episodes appeared to be
an independent significant risk factor in multivariable
analysis (p = 0.023) with higher numbers of graft rejec-
tion episodes protecting patients from PTLD (OR = 0.38)
which can be explained by lower intensity of immuno-
suppressive therapy. The likelihood of rejection episodes
decreased significantly with higher percentages of time
on tacrolimus-based immunosuppression during follow-
up (p = 0.015, logistic regression) which is in line with
previous reports in the literature [59]. This study showed
that lower numbers of graft rejection episodes were
linked to a higher risk for PTLD, and at the same time,
lower numbers of graft rejection episodes were linked to
tacrolimus-based immunosuppression reinforcing the
finding that tacrolimus dosage at hospital discharge in-
creased the risk of PTLD development. Therefore, pa-
tients on tacrolimus with none or few rejection episodes
might benefit from closer monitoring for PTLD during
follow-up.
HLA A2 haplotype in transplant recipients was a pro-
tective factor in this study instead of increasing the risk
for PTLD as was reported previously [11, 12]. HLA A2
Fig. 4 Shown are the results of matched-pair analysis for daily dosages of tacrolimus at hospital discharge after transplantation (p = 0.052;
paired t test). The colored lines link values between PTLD patients and matching non-PTLD partners, demonstrating the difference in each pair.
Tx transplantation
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haplotype encodes a HLA class I protein which presents
peptides from expired or defective intracellular proteins
as well as proteins from invasive viruses from within the
cell to the T cell receptor on CD8+, often cytotoxic, T cells
in order to destroy the (infected) cell [60]. The result of
our study together with previously published findings sug-
gests that HLA A2 haplotype might be responsible for an
effective presentation of EBV antigens to CD8+ cytotoxic
T cells and thus that HLA A2-positive individuals may
control EBV infection better than negative counterparts
[61]. The identification that lack of HLA A2 in the recipi-
ent is significantly associated with PTLD is hypothesis
generating and should be a basis for larger studies.
Further analysis revealed that the percentage of
tacrolimus-based immunosuppression during follow-
up and the dosage of tacrolimus at hospital discharge
were not related to HLA A2 positivity (p = 0.169 and
p = 0.167, respectively). This finding excludes the pos-
sibility that HLA A2 positivity is a surrogate marker
for more or less intense immunosuppression.
All other HLA types and possible donor-recipient HLA
mismatching combinations which have been previously
described as either protective or as risk factors for PTLD
development [1, 4, 13–16] did not show any significant in-
fluence on PTLD development in this matched-pair ana-
lysis. Previous reports did not apply a matched-pair
approach. However, this observation is limited by the fact
that not for all liver-transplanted patients the HLA status
was given and thus taken into account (Table 2).
Multivariable risk factor analysis
Conditional multivariable regression revealed recipient
HLA A2 haplotype, the level of tacrolimus dosage at hos-
pital discharge after transplantation, and the number of
graft rejection episodes as independent risk factors for the
development of PTLD, provided that the aforementioned
matching criteria are met. Addition of the number of
CMV infections or reactivations after transplantation as
an easily trackable factor to the derived multivariable pre-
diction model did not improve the model while revealing
a statistically non-significant influence in multivariable re-
gression. Therefore, we have eliminated this variable from
the final prediction model.
Fig. 5 Shown is the result of ROC-curve analysis of the multivariable logistic regression model for the prediction of PTLD in matched-pair analysis
(AUROC: 0.823) indicating a good discriminative power as well as good overall model correctness and thus potential clinical usefulness provided
that the matched-pair criteria are met
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The non-significant result of the model fit assessment
(p = 0.483) excluded the possibility of overfitting, and the
AUROC (0.823) of the derived predictive model indicated
a good discriminative power as well as good overall model
correctness, and thus potential clinical usefulness [43, 44].
It allows an early identification of patients at increased risk
for PTLD. We accept that the limitations of the proposed
predictive model include the relatively small number of
analyzed cases and a lack of external validation with data
from another transplant center. The proposed model
should therefore be regarded cautiously.
Limitations
The limitations of this work mostly refer to the limited
number of PTLD cases in a single-center study and its
retrospective nature. Despite the design of this study as
matched-pair analysis and the introduction of several
substantial matching criteria, individual differences in
patients still contribute to some uncertainty. A larger,
prospective, multicenter trial will be necessary to define
risk factors for PTLD development and to refine screen-
ing methods based on more substantial findings. Caution
in the clinical application of the derived prognostic
model is warranted due to its current lack of external
validation.
Conclusions
This study shows that the most likely scenario for the
development of PTLD is caused by high tacrolimus dos-
ages at hospital discharge, fewer subsequent rejection
episodes which are associated with higher percentages of
time on tacrolimus treatment during follow-up, absent
HLA A2 haplotype in the recipient, and CMV infections
or reactivations during follow-up. EBV-related PTLD
risk could not be quantified adequately in this study
while all investigated tumors were EBV positive. Patients
with unfavorable combinations of risk factors should be
monitored more closely for PTLD and their EBV status.
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